Ani Pharmaceuticals Inc (ANIP) — 8-K Filings

8-K Filings (32)

• 8-K Filing — May 8, 2026
• 8-K Filing — Dec 1, 2025
• ANI Pharmaceuticals Files 8-K on Financials — Nov 10, 2025 Risk: low
  ANI Pharmaceuticals, Inc. filed an 8-K on November 10, 2025, reporting on its Results of Operations and Financial Condition, Regulation FD Disclosure, and Finan
• ANI Pharmaceuticals Reports Equity Sales & Rights Modifications — Sep 26, 2025 Risk: medium
  ANI Pharmaceuticals, Inc. filed an 8-K on September 26, 2025, reporting on unregistered sales of equity securities and material modifications to the rights of s
• ANI Pharmaceuticals Files 8-K on Financials — Sep 8, 2025 Risk: low
  On September 8, 2025, ANI Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition,
• ANI Pharmaceuticals Files 8-K — Jul 29, 2025 Risk: medium
  ANI Pharmaceuticals, Inc. filed an 8-K on July 29, 2025, reporting an "Other Event." The filing does not contain specific details about the event, dollar amount
• ANI Pharmaceuticals Files 8-K Report — Jul 23, 2025 Risk: low
  On July 23, 2025, ANI Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 210 Main Street W
• ANI Pharmaceuticals Files 8-K on Financials — Jun 4, 2025 Risk: low
  ANI Pharmaceuticals, Inc. filed an 8-K on June 4, 2025, reporting on its results of operations and financial condition. The filing also includes information reg
• ANI Pharmaceuticals Files 8-K: Director Departures, New Elections — May 23, 2025 Risk: medium
  On May 22, 2025, ANI Pharmaceuticals, Inc. filed an 8-K report detailing several key events. These include the departure of Director Michael L. Miller, the elec
• ANI Pharmaceuticals Files 8-K on Financials — May 20, 2025 Risk: low
  ANI Pharmaceuticals, Inc. filed an 8-K on May 20, 2025, reporting on its results of operations and financial condition. The filing also includes financial state
• ANI Pharma Acquires Aggrastat Rights from Merck — May 8, 2025 Risk: medium
  ANI Pharmaceuticals, Inc. announced on May 6, 2025, that it has entered into a definitive agreement to acquire the U.S. rights to the prescription drug "Aggrast
• ANI Pharmaceuticals Files 8-K — Mar 18, 2025 Risk: low
  ANI Pharmaceuticals, Inc. filed an 8-K on March 18, 2025, reporting other events and financial statements. The filing does not contain specific financial detail
• ANI Pharmaceuticals Files 8-K — Mar 14, 2025 Risk: low
  ANI Pharmaceuticals, Inc. filed an 8-K on March 14, 2025, reporting on other events and financial statements. The filing details the company's principal executi
• ANI Pharmaceuticals Files 8-K on Financials — Mar 11, 2025 Risk: low
  ANI Pharmaceuticals, Inc. filed an 8-K on March 11, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD
• ANI Pharmaceuticals Files 8-K on Financials — Feb 5, 2025 Risk: low
  On February 5, 2025, ANI Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, a
• ANI Pharmaceuticals Files 8-K on Financials — Jan 13, 2025 Risk: low
  ANI Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation
• ANI Pharmaceuticals Files 8-K on Financials — Nov 20, 2024 Risk: low
  ANI Pharmaceuticals, Inc. filed an 8-K on November 20, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation
• ANI Pharma Acquires Amneal Generic Drug Assets — Sep 20, 2024 Risk: medium
  ANI Pharmaceuticals, Inc. announced on September 20, 2024, the completion of its acquisition of certain assets from Amneal Pharmaceuticals LLC. The transaction,
• ANI Pharmaceuticals Files 8-K — Sep 16, 2024 Risk: low
  ANI Pharmaceuticals, Inc. filed an 8-K on September 16, 2024, reporting other events and financial statements. The filing does not contain specific details on n
• ANI Pharmaceuticals Reports Material Agreement Changes — Aug 13, 2024 Risk: medium
  On August 7, 2024, ANI Pharmaceuticals, Inc. entered into a Material Definitive Agreement related to the termination of a previous agreement. The company also r
• ANI Pharmaceuticals Acquires Alaven Pharmaceuticals — Aug 8, 2024 Risk: medium
  ANI Pharmaceuticals, Inc. announced on August 7, 2024, that it has completed the acquisition of Alaven Pharmaceuticals LLC for an undisclosed amount. This acqui
• ANI Pharmaceuticals Files 8-K — Aug 7, 2024 Risk: low
  ANI Pharmaceuticals, Inc. filed an 8-K on August 7, 2024, reporting other events and financial statements. The filing details the company's operations and finan
• ANI Pharmaceuticals Files 8-K on Financials — Aug 6, 2024 Risk: low
  ANI Pharmaceuticals, Inc. filed an 8-K on August 6, 2024, reporting on its results of operations and financial condition, and including financial statements and
• ANI Pharma Acquires Atorvastatin Rights — Jun 24, 2024 Risk: medium
  On June 21, 2024, ANI Pharmaceuticals, Inc. entered into a Material Definitive Agreement related to its acquisition of the U.S. rights to the prescription drug,
• ANI Pharma Acquires Opana ER Rights for $8M — Jun 5, 2024 Risk: medium
  ANI Pharmaceuticals, Inc. announced on June 5, 2024, that it has entered into a definitive agreement to acquire the U.S. rights to the prescription drug Opana E
• ANI Pharma to Acquire Amneal's US Rx Business for $230M — May 23, 2024 Risk: medium
  ANI Pharmaceuticals, Inc. announced on May 21, 2024, that it has entered into a definitive agreement to acquire the U.S. prescription business ofptives of Amnea
• ANI Pharmaceuticals Files 8-K on Financials — May 14, 2024 Risk: low
  ANI Pharmaceuticals, Inc. filed an 8-K on May 14, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD d
• ANI Pharmaceuticals Files 8-K on Financials — Apr 17, 2024 Risk: low
  On April 17, 2024, ANI Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, alo
• ANI Pharmaceuticals Files 8-K on Financials — Mar 12, 2024 Risk: low
  ANI Pharmaceuticals, Inc. filed an 8-K on March 12, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD
• ANI Pharma Enters Material Definitive Agreement — Feb 23, 2024 Risk: medium
  ANI Pharmaceuticals, Inc. filed an 8-K on February 23, 2024, reporting an event that occurred on February 16, 2024. The filing indicates an "Entry into a Materi
• ANI Pharma Files 8-K on Financial Results & Reg FD Disclosure — Feb 8, 2024 Risk: low
  ANI Pharmaceuticals, Inc. filed an 8-K on February 8, 2024, to disclose information under Item 2.02, "Results of Operations and Financial Condition," and Item 7
• ANI Pharma Files 8-K on Operations & Financial Condition — Jan 8, 2024
  ANI Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition, as well as to make a Regulation FD di

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX